Five months after the FDA blocked its plans for accelerated approval, Agenus is moving ahead with discussions with potential ...

Merck's Keytruda and Eisai's Lenvima combo with chemo failed survival endpoint in gastroesophageal cancer study, but ...

Aardvark Therapeutics files for IPO. Company develops hunger-targeting obesity drug ARD-101 and ARD-201, led by CEO Tien Lee.

Takeda has ended the manufacturing and supply of its gout drug Uloric in the US market as more patients turn to generic ...

President Donald Trump's communications pause for HHS, FDA and other health-related agencies could push some drug approval ...

Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical ...

Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed ...

UnitedHealth Group has named a new CEO to lead its health insurance business, following the murder of the division’s former ...

Boehringer Ingelheim merges AMAL and ViraTherapeutics cancer units, Dantari sells assets to Adanate, Madrona raises $770M, and Abdera adds JJDC and Foresite as investors.

AstraZeneca is looking to increase its presence north of the US border. The UK pharma said it is budgeting $570 million to ...

ALX Oncology is forging ahead with a treatment approach that has long been abandoned by other drugmakers, eyeing a potential ...

Teva, Astellas and AstraZeneca say they will participate in the next round of Medicare negotiations under the Inflation ...